Kura Oncology, Inc. (NASDAQ:KURA) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, KURA to report 3Q20 loss of $ 0.4 per share.
For the full year, analysts anticipate loss of $ 1.65 per share bottom line.
Stock Performance
Shares of Kura Oncology, Inc. traded low $ -0.60 or -1.80 percent on Wednesday, reaching $ 32.76 with volume of 2.29 million shares. Kura Oncology, Inc. has traded high as $ 33.90 and has cracked $ 29.10 on the downward trend
The closing price of $ 32.76, representing a 425.35 % increase from the 52 week low of $ 6.35 and a 5.36 % decrease over the 52 week high of $ 35.25.
The company has a market capital of $ 1.84 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 12th October 2020, maintained by HC Wainwright at Buy rating, with $ 40.00 target price.
- On 8th October 2020, maintained by Credit Suisse Group at Outperform rating, with $ 43.00 target price.
Conference Call
Kura Oncology, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.kuraoncology.com
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The companys lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
